Historical
 
 
  LAST PUBLICATIONS  
 

Nature Medicine - Epigenetic activation of a cryptic TBC1D16 transcript enhances melanoma progression by targeting EGF >>

 

Genome Biology - Epigenomic analysis detects aberrant super-enhancer DNA methylation in human cancer >>

 

Oncogene - . Gene Amplification-Associated Overexpression of the RNA Editing Enzyme ADAR1 Enhances Human Lung T >>

 

Neuropsychopharmacology - Improvement of the Rett syndrome phenotype in a MeCP2 mouse model upon treatment with levodopa and a >>

 

Molecular Cell - Liz J, Portela A, Soler M, Gómez A, Ling H, Michlewski G, Calin GA, Guil S, Esteller M. >>

 

Nature Communications - A DERL3-associated defect in the degradation of SLC2A1 mediates the Warburg effect. Lopez-Serra P, M >>

 

Cell Reports - Linkage of DNA Methylation Quantitative Trait Loci to Human Cancer Risk.Heyn H, Sayols S, Moutinho C >>

 

 
     

  NEWS  
 
12/02/16
Manel Esteller receives the National Research Prize 2015
 

Dr Manel Esteller

The Government of Catalonia and the Catalan Foundation for Research and Innovation (FCRI) have awarded Manel Esteller the National Research Award 2015. Manel Esteller is an ICREA research professor, director of the Epigenetics and Cancer Biology Program of the Institute of Biomedical Research of Bellvitge since 2008, head of the cancer Epigenetics Group of the center and professor of Genetics at the Department of Physiological Sciences II of the Faculty of Medicine of the University of Barcelona. Manel Esteller has carried out pioneering research and international leadership in epigenetics (the study of heritable changes in gene function derived from external or environmental factors unrelated to DNA sequence) as a key factor in cancer development. His work has been decisive in studying methylation as a mechanism of altering human tumor suppressor genes. Currently, the awarded focuses its research on the development of the epigenomic maps of normal and transformed cells, the study of epigenetic modifications and development of new epigenetic drugs for treating cancer. The National Research Prize recognizes the researcher who has recently contributed, significantly and internationally, to the advancement of a scientific discipline in all its areas: humanities and social sciences, life sciences and health, engineering and technology and experimental sciences. Manel Esteller graduated in Medicine and Surgery at the University of Barcelona, and obtained his doctorate at the same university with a thesis on molecular genetics of endometrial carcinoma. He is the author of more than four hundred articles in the field of medical sciences, member of several scientific societies and critical of numerous international scientific journals. He has also received several awards, including the Rei Jaume I Prize for basic research (2013), the twentieth Severo Ochoa Prize for Biomedical Research (2013), the Vanguardia Award for Science (2014) and, among others, the Josep Trueta Medal for health merit (2015 ).

 

12/02/16
Eva Gonzalez Suarez gets Consolidator Grant from the European Research Council
 

Dr Manel Esteller

The head of the group of Transformation and Metastasis PEBC-IDIBELL, Eva Gonzalez Suarez has received an ERC Consolidator Grant from the European Research Council (ERC) to develop its PLEIO-RANK project to develop a single therapy capable of reducing metastasis and mortality in solid tumors. The grant supposes a funding 2 million Euros for the next five years. Thousands of cancer patients worldwide are taking RANKL inhibitors for the management of bone metastases, based on the key role of RANKL and its receptor RANK in osteoclasts. "We have shown" explains the researcher "that overexpression of RANK induces stemness, interferes with differentiation in transformed mammary epithelial cells, and promotes the early stages of mammary tumorigenesis acting as a paracrine mediator of progesterone." "The PLEIO-RANK project" adds, "is intended to explore the therapeutic potential of inhibiting RANK signaling in other solid tumors, not only as a preventive strategy, but also during tumor progression, recurrence and metastases. We will dissect the role of this pathway in tumor cells and in surrounding stroma." Inhibition of RANK could become a single therapy aimed at reducing mortality and metastasis in solid tumors by its pleiotropic antitumor effects on cancer and stromal cells. The Consolidator Grants aim to promote the career of talented researchers with an innovative vision who have demonstrated their research potential and scientific maturity.

 

13/05/15
Manel Esteller receives Josep Trueta health merit medal
 

Dr Manel Esteller

The director of the Epigenetics and Cancer Biology, Manel Esteller received the medal Josep Trueta to the sanitary merit of this year. The ceremony took place on May 12th at the Palau de la Generalitat, headed by Artur Mas, president of the Generalitat, and Boi Ruiz, head of Health Department. Josep Trueta medals and plaques, given annually by the Generalitat of Catalonia, distinguished persons and entities that, on its merits, have highlighted significantly for services rendered in order to progress and improving health. The Josep Trueta medals and plaques were created in 1997, coinciding with the centenary of the birth of renowned Catalan doctor and scientist.

 

11/05/2015
Help us to investigate new treatments for children affected by Rett Syndrome: our new Crowdfunding Project in Verkami.
 

Dr Manel Esteller

The Rett Syndrome is the second most common cause of intellectual disability in females after Down Syndrome. It is a neuronal developmental disease whose clinical symptoms begin to appear 6-18 months after birth and is characterized by an intellectual, social and motor skills impairments accompanied by autistic behaviours, such as repeated hand movements. It affects approximately 1 in 10,000 or 15,000 girls and is usually due to the presence of a mutation in the gene MECP2, an epigenetic gene which controls the activity of many other genes of the cell. Today there is no effective treatment for Rett syndrome, but the latest scientific developments indicate that we may be able to reverse the syndrome. To date, we have investigated various compounds that appear to improve some of the effects of the MECP2 mutation but we are still far away to understand that complex disease and to test all possible drugs. Help us to improve the life of girls affected by Rett Syndrome. Your donations of 10 or 25 Euros can make the difference. http://www.verkami.com/projects/9255-investigacion-de-nuevos-tratamientos-para-el-sindrome-de-rett

 

07/10/2014
PEBC in "Cancer Research”, "Human Molecular Genetics” and “FEBS J”
 

Dr Manel Esteller

The research developed at the PEBC has been recognized in the prestigious journals Cancer Research”, “Human Molecular Genetics” y “FEBS J”. For further information: -A Comprehensive DNA Methylation Profile of Epithelial-to-Mesenchymal Transition. Carmona FJ, Davalos V, Vidal E, Gomez A, Heyn H, Hashimoto Y, Vizoso M, Martinez-Cardus A, Sayols S, Ferreira HJ, Sánchez-Mut JV, Morán S, Margelí M, Castella E, Berdasco M, Stefansson OA, Eyfjord JE, Gonzalez-Suarez E, Dopazo J, Orozco M, Gut IG, Esteller M. Cancer Res. Oct 1;74(19):5608-19, 2014. -Altered expression of the imprinted transcription factor PLAGL1 deregulates a network of genes in the human IUGR placenta. Iglesias-Platas I, Martin-Trujillo A, Petazzi P, Guillaumet-Adkins A, Esteller M, Monk D. Hum Mol Genet. pii: ddu347, 2014. -Gains of DNA methylation in myeloid terminal differentiation are dispensable for gene silencing but influence the differentiated phenotype. Vento-Tormo R, Alvarez-Errico D, Rodríguez-Ubreva J, Ballestar E. FEBS J. Sep 13. doi: 10.1111/febs.13045, 2014.

 

 
 
     
 
 
 

© 2008® | PEBC | Todos los derechos reservados |  WEBMAIL  |  INTRANET  |  FTP